Kimberly Manhard is the Senior Vice President of Global Strategic Planning and Execution, overseeing strategic product planning for the organization. She joined Acadia in 2024.
With a distinguished career that spans decades, Ms. Manhard has demonstrated leadership in drug development, quality assurance and pharmacovigilance, regulatory affairs, and development operations across several prestigious organizations. Prior to joining Acadia, Ms. Manhard was the Executive Vice President of Drug Development at Heron Therapeutics, contributing significantly to their success and also served as a member of the board of directors.
Since beginning her career in clinical research at Eli Lilly and Company, Ms. Manhard has held leadership roles at an array of pharmaceutical companies, including Bristol Myers Squibb, Boehringer Ingelheim, Agouron Pharmaceuticals (acquired by Pfizer, Inc.), and Ardea Biosciences (acquired by AstraZeneca). Currently, she lends her expertise as a board member for Shoreline Biosciences, Inhibrx, and Toragen.
Ms. Manhard is an alumna of the University of Florida, Gainesville, holding a B.S. in Zoology and a B.A. in French.